Patents Assigned to Oncotherapy Science, Inc.
  • Patent number: 8685641
    Abstract: Objective methods for detecting and diagnosing bladder cancer (BLC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of a BLC-associated gene that discriminates between BLC cells and normal cells. The present invention further provides means for predicting and preventing bladder cancer metastasis using BLC-associated genes having unique altered expression patterns in bladder cancer cells with lymph-node metastasis. The present invention provides methods of screening for therapeutic agents useful in the treatment of bladder cancer, methods of treating bladder cancer and method for vaccinating a subject against bladder cancer. Specifically, the present application provides novel human genes C2093, B5860Ns and C6055s whose expression is markedly elevated in bladder cancers.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: April 1, 2014
    Assignee: OncoTherapy Science, Inc.
    Inventors: Yusuke Nakamura, Toyomasa Katagiri, Shuichi Nakatsuru
  • Patent number: 8674069
    Abstract: According to the present invention, peptides having the amino acid sequence of SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62 were demonstrated to have cytotoxic T lymphocyte (CTL) inducibility. Therefore, the present invention provides a peptide having the amino acid sequence selected from among SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62. The peptide can include one, two, or several amino acid substitutions, deletions, insertions, or additions so long as its CTL inducibility is retained. Furthermore, the present invention provides pharmaceutical agents for the treatment and/or prophylaxis of cancers, and/or prevention of postoperative recurrence thereof, which contain any of these peptides. Pharmaceutical agents of this invention include vaccines.
    Type: Grant
    Filed: July 30, 2009
    Date of Patent: March 18, 2014
    Assignee: OncoTherapy Science, Inc.
    Inventors: Takuya Tsunoda, Ryuji Ohsawa
  • Patent number: 8674059
    Abstract: Objective methods for detecting and diagnosing colon cancer are described herein. In one embodiment, the diagnostic method involves determining the expression level of TOM34 that discriminates between colon cancer cells and normal cells. Finally, the present invention provides methods of screening for therapeutic agents useful in the treatment of colon cancer, methods of treating colon cancer and method for vaccinating a subject against colon cancer.
    Type: Grant
    Filed: July 21, 2006
    Date of Patent: March 18, 2014
    Assignee: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Yoichi Furukawa, Hideaki Tahara, Takuya Tsunoda, Satoshi Matsushima
  • Patent number: 8673548
    Abstract: The present application provides novel human genes A7322, whose expression is markedly elevated in breast cancer. The present application also provides human genes F3374 whose expression is markedly elevated in breast cancer. These genes and polypeptides encoded thereby can be used, for example, in the diagnosis of breast cancer, and as target molecules for developing drugs against breast cancer. The invention features methods of screening for modulators of the kinase activity of PBK/TOPK. The invention further provides methods of screening for agents to prevent or treat cancer, such as breast cancer.
    Type: Grant
    Filed: August 10, 2007
    Date of Patent: March 18, 2014
    Assignee: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Toyomasa Katagiri, Shuichi Nakatsuru
  • Patent number: 8663647
    Abstract: The present invention provides immunogenic peptides comprising the amino acid sequence of SEQ ID NO: 1, 2, 13, 32, and peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted or added, and having cytotoxic T cell inducibility, and also provides drugs for treating or preventing tumors comprising these peptides. The peptides of this invention can be used as vaccines.
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: March 4, 2014
    Assignee: Oncotherapy Science, Inc.
    Inventors: Hideaki Tahara, Takuya Tsunoda, Masabumi Shibuya, Shuichi Nakatsuru
  • Patent number: 8653234
    Abstract: The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 7, 8, 9, 10, 11, 12, 192, 195, 197, 209, 225, 226, 228, 230, 240, 241, 243, 244, 249, 253, 254 or 255, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, wherein the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with the over-expression of MPHOSPH1 and/or DEPDC1, e.g. cancers, containing these peptides as an active ingredient. The peptides of the present invention can also be used as vaccines.
    Type: Grant
    Filed: June 27, 2012
    Date of Patent: February 18, 2014
    Assignee: OncoTherapy Science, Inc.
    Inventors: Tomoaki Fujioka, Yusuke Nakamura, Takuya Tsunoda, Ryuji Osawa, Midori Shida
  • Patent number: 8642724
    Abstract: Objective methods for detecting and diagnosing colon cancer are described herein. In one embodiment, the diagnostic method involves determining the expression level of TOM34 that discriminates between colon cancer cells and normal cells. Finally, the present invention provides methods of screening for therapeutic agents useful in the treatment of colon cancer, methods of treating colon cancer and method for vaccinating a subject against colon cancer.
    Type: Grant
    Filed: July 21, 2006
    Date of Patent: February 4, 2014
    Assignee: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Yoichi Furukawa, Hideaki Tahara, Takuya Tsunoda, Satoshi Matsushima
  • Publication number: 20140023672
    Abstract: An objective of the present invention is to provide a means for enabling cancer immunotherapy that targets approximately 30% of various cancer patients that highly express forkhead box M1 (FOXM1) among the Japanese, by identifying FOXM1-derived peptides that can activate cancer cell-damaging human killer T cells by binding to HLA-A2. The present invention provides a peptide of (A) or (B) below: (A) a peptide including the amino acid sequence of any one of SEQ ID NOs: 1 to 3; (B) a peptide which includes the amino acid sequence of any one of SEQ ID NOs: 1 to 3, wherein one, two, or several amino acid(s) are substituted, deleted, inserted, and/or added, and wherein the peptide shows cytotoxic (killer) T cell-inducing activity.
    Type: Application
    Filed: September 25, 2013
    Publication date: January 23, 2014
    Applicant: ONCOTHERAPY SCIENCE, INC.
    Inventors: Yasuharu Nishimura, Kazunori Yokomine, Takuya Tsunoda, Yusuke Nakamura
  • Patent number: 8623829
    Abstract: The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 143, 147, 148, 149, 150, 152, 153, 154, 156, 160, 161, 162, 163, 166, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the CDH3, EPHA4, ECT2, HIG2, INHBB, KIF20A, KNTC2, TTK and/or URLC10, e.g. cancers containing as an active ingredient one or more of these peptides. The peptides of the present invention find further utility as vaccines.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: January 7, 2014
    Assignee: Oncotherapy Science, Inc.
    Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura
  • Patent number: 8617562
    Abstract: The present invention provides isolated peptides having the amino acid sequence of SEQ ID NO: 34 or fragments thereof, which bind to HLA antigen and induce cytotoxic T lymphocyte (CTL). The present invention further provides peptides which include one, two, or several amino acid insertions, substitution or addition to the aforementioned peptides or fragments, but still have the cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical substances or compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical substances or compositions of the present invention may be used for treating cancer or tumor.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: December 31, 2013
    Assignee: OncoTherapy Science, Inc.
    Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe
  • Patent number: 8614176
    Abstract: The present invention provides peptides comprising the amino acid sequence of SEQ ID NO: 8, 67, 89, as well as peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, and having cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors comprising these peptides. The peptides of the present invention can also be used as vaccines.
    Type: Grant
    Filed: October 13, 2010
    Date of Patent: December 24, 2013
    Assignee: OncoTherapy Science, Inc.
    Inventors: Hideaki Tahara, Takuya Tsunoda, Yusuke Nakamura, Yataro Daigo, Shuichi Nakatsuru
  • Publication number: 20130315942
    Abstract: The present invention provides peptides containing the amino acid sequence of SEQ ID NOs: 1, 2, 3, 4, 16, 17, 30, 31, 34, 36, 37, 40, 41, 45, 49, 55, 57 and 61, as well as peptides containing the above-mentioned amino acid sequences in which 1, 2, or several amino acid(s) are substituted, deleted, inserted or added, but still have cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors, which drugs containing these peptides. The peptides of the present invention can also be used as vaccines.
    Type: Application
    Filed: May 23, 2013
    Publication date: November 28, 2013
    Applicant: OncoTherapy Science, Inc.
    Inventor: OncoTherapy Science, Inc.
  • Publication number: 20130309259
    Abstract: Peptide vaccines against cancer are described herein. In particular, isolated epitope peptides or immunogenic fragments derived from SEQ ID NO: 32, that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) are provided. The amino acid sequence of the peptide of interest may be optionally modified with the substitution, deletion, insertion, or addition of one, two, or several amino acids sequences. Pharmaceutical compositions and methods of treating cancer that include such peptides are also provided.
    Type: Application
    Filed: October 20, 2011
    Publication date: November 21, 2013
    Applicant: OncoTherapy Science, Inc.
    Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Osawa, Sachiko Yoshimura, Tomohisa Watanabe
  • Patent number: 8586547
    Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 18, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences. The present invention also provides pharmaceutical compositions including these peptides. The peptides of the present invention can be used for treating cancer.
    Type: Grant
    Filed: May 25, 2010
    Date of Patent: November 19, 2013
    Assignee: Oncotherapy Science, Inc.
    Inventors: Yasuharu Nishimura, Yusuke Tomita, Yusuke Nakamura, Takuya Tsunoda
  • Patent number: 8574585
    Abstract: The present invention provides nonapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO:2, 3, 5, 8, 11, or 12; nonapeptides or decapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO:29, 30, 33, 34, 40, or 46; and peptides with cytotoxic T cell inducibility, in which one, two, or several amino acids are substituted or added to the above-mentioned amino acid sequences, as well as pharmaceuticals for treating or preventing tumors, where the pharmaceuticals comprise these peptides. The peptides of this invention can be used as vaccines.
    Type: Grant
    Filed: June 12, 2012
    Date of Patent: November 5, 2013
    Assignee: Oncotherapy Science, Inc.
    Inventors: Hideaki Tahara, Satoshi Wada, Takuya Tsunoda
  • Patent number: 8574586
    Abstract: The present invention provides nonapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO:2, 3, 5, 8, 11, or 12; nonapeptides or decapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO:29, 30, 33, 34, 40, or 46; and peptides with cytotoxic T cell inducibility, in which one, two, or several amino acids are substituted or added to the above-mentioned amino acid sequences, as well as pharmaceuticals for treating or preventing tumors, where the pharmaceuticals comprise these peptides. The peptides of this invention can be used as vaccines.
    Type: Grant
    Filed: June 12, 2012
    Date of Patent: November 5, 2013
    Assignee: Oncotherapy Science, Inc.
    Inventors: Hideaki Tahara, Satoshi Wada, Takuya Tsunoda
  • Patent number: 8569244
    Abstract: An objective of the present invention is to provide a means for enabling cancer immunotherapy that targets approximately 30% of various cancer patients that highly express forkhead box M1 (FOXM1) among the Japanese, by identifying FOXM1-derived peptides that can activate cancer cell-damaging human killer T cells by binding to HLA-A2. The present invention provides a peptide of (A) or (B) below: (A) a peptide including the amino acid sequence of any one of SEQ ID NOs: 1 to 3; (B) a peptide which includes the amino acid sequence of any one of SEQ ID NOs: 1 to 3, wherein one, two, or several amino acid(s) are substituted, deleted, inserted, and/or added, and wherein the peptide shows cytotoxic (killer) T cell-inducing activity.
    Type: Grant
    Filed: August 12, 2008
    Date of Patent: October 29, 2013
    Assignee: OncoTherapy Science, Inc.
    Inventors: Yasuharu Nishimura, Kazunori Yokomine, Takuya Tsunoda, Yusuke Nakamura
  • Patent number: 8563516
    Abstract: The present invention provides Foxp3 peptides comprising the amino acid sequence of SEQ ID NOs: 3-5, 7-9, 12, 15-19, 22, 24, 27-30, 37, 67 or 74, and Foxp3 peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted or added, and having cytotoxic T cell inducibility, and also provides drugs for regulating regulatory T cells comprising these Foxp3 peptides. The Foxp3 peptides of this invention find use as vaccines.
    Type: Grant
    Filed: December 26, 2007
    Date of Patent: October 22, 2013
    Assignee: OncoTherapy Science, Inc.
    Inventors: Takuya Tsunoda, Ryuji Osawa
  • Patent number: 8557955
    Abstract: The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 7, 8, 9, 10, 11, 12, 192, 195, 197, 209, 225, 226, 228, 230, 240, 241, 243, 244, 249, 253, 254 or 255, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, wherein the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with the over-expression of MPHOSPH1 and/or DEPDC1, e.g. cancers, containing these peptides as an active ingredient. The peptides of the present invention can also be used as vaccines.
    Type: Grant
    Filed: October 16, 2007
    Date of Patent: October 15, 2013
    Assignee: OncoTherapy Science, Inc.
    Inventors: Tomoaki Fujioka, Yusuke Nakamura, Takuya Tsunoda, Ryuji Osawa, Midori Shida
  • Patent number: 8552146
    Abstract: The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 7, 8, 9, 10, 11, 12, 192, 195, 197, 209, 225, 226, 228, 230, 240, 241, 243, 244, 249, 253, 254 or 255, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, wherein the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with the over-expression of MPHOSPH1 and/or DEPDC1, e.g. cancers, containing these peptides as an active ingredient. The peptides of the present invention can also be used as vaccines.
    Type: Grant
    Filed: July 30, 2012
    Date of Patent: October 8, 2013
    Assignee: OncoTherapy Science, Inc.
    Inventors: Tomoaki Fujioka, Yusuke Nakamura, Takuya Tsunoda, Ryuji Osawa, Midori Shida